Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)
Brolucizumab was approved based on the outcome of HAWK and HARRIER phase three studies. Credit: Novartis.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more